A 34-year-old female software engineer presents to the clinic with a 6-week history of pro… — USMLE Step 2 CK

A 34-year-old female software engineer presents to the clinic with a 6-week history of profound fatigue, sleeping 12 to 14 hours a day, significant weight gain, and an inability to focus on her work. She reports feeling hopeless and admits to passive thoughts of death, though she denies active suicidal ideation or any specific plan. She has no significant past medical history. A review of her medical records indicates that three years ago she was brought to the emergency department by her family for severe agitation, grandiosity, and going four consecutive days without sleep. She was hospitalized, diagnosed with a psychiatric condition, and prescribed medication, which she discontinued shortly after discharge. Vital signs are within normal limits. Physical examination is unremarkable. Laboratory evaluation reveals a thyroid-stimulating hormone (TSH) level of $1.8 \mu\text{U/mL}$ (normal: $0.4-4.0 \mu\text{U/mL}$ ) and a free T4 level of $1.2 \text{ ng/dL}$ (normal: $0.9-2.4 \text{ ng/dL}$ ). Which of the following is the most appropriate pharmacological management for this patient?

A
Escitalopram
B
Amitriptyline
LurasidoneCevap
D
Fluoxetine and phenelzine combination
E
Levothyroxine

Cevap

The most appropriate pharmacological management is Lurasidone, as it effectively treats acute bipolar depression without the risk of precipitating mania.

The correct answer is Lurasidone. This patient is presenting with a major depressive episode characterized by hypersomnia, weight gain, depressed mood, and fatigue. Crucially, she has a clear history of a prior manic episode (severe agitation, grandiosity, and going four days without sleep requiring hospitalization). This firmly establishes a diagnosis of Bipolar I Disorder, current episode depressed. The standard of care for acute bipolar depression involves utilizing medications that effectively treat depression without inducing mania. First-line options include certain second-generation antipsychotics like lurasidone or quetiapine, or mood stabilizers like lithium. Lurasidone is FDA-approved specifically for bipolar depression and is a safe, effective choice.

Adım Adım Çözüm

Analyze the patient's current symptoms.

The patient exhibits severe fatigue, hypersomnia, weight gain, poor concentration, and passive death wishes, meeting the criteria for a major depressive episode.

To determine the current clinical state requiring intervention.

Evaluate the patient's psychiatric history.

The patient has a clear history of a severe manic episode (agitation, grandiosity, decreased need for sleep leading to hospitalization).

To differentiate between unipolar major depressive disorder and bipolar disorder.

Synthesize findings to confirm the diagnosis.

A history of a manic episode combined with a current depressive episode establishes the diagnosis of Bipolar I Disorder, current episode depressed.

Accurate diagnosis dictates the pharmacological approach and prevents harmful prescribing errors.

Select the appropriate pharmacological treatment based on the diagnosis.

Lurasidone is chosen over antidepressant monotherapy.

Lurasidone is an approved, effective treatment for bipolar depression, whereas antidepressant monotherapy is contraindicated due to the risk of precipitating a manic switch.

Anahtar Kavram

Patients presenting with depressive symptoms must be screened for a history of mania or hypomania to rule out bipolar disorder. First-line treatments for acute bipolar depression include lurasidone, quetiapine, or mood stabilizers like lithium, while antidepressant monotherapy must be strictly avoided.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru